Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
January 07, 2019 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety...
Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
January 07, 2019 06:30 ET
|
Emergent BioSolutions
Full year 2018 preliminary performance in line with recently revised guidanceFull year 2019 forecast reflects continued growth of organic business and anticipated positive impact of recent...